Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 156-162

  Holland, Pamela M ^a  

^a AMGEN INC   (United States)

Author keywords

Apo2L TRAIL; Apoptosis; Cancer; Dulanermin

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DULANERMIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; RITUXIMAB; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOSURVEILLANCE; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84876072005     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.11.001     Document Type: Review

References (70)

1. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
2. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26:3621-3630.
3. Newsom-Davis T., Prieske S., Walczak H. Is TRAIL the holy grail of cancer therapy?. Apoptosis 2009, 14:607-623.
4. Pavet V., Beyrath J., Pardin C., et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res. 2010, 70:1101-1110.
5. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
6. Pitti R.M., Marsters S.A., Ruppert S., et al. a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
7. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 2000, 50:184-195.
8. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
9. Hymowitz S.G., O'Connell M.P., Ultsch M.H., et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000, 39:633-640.
10. Jo M., Kim T.H., Seol D.W., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000, 6:564-567.
11. Lawrence D., Shahrokh Z., Marsters S., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7:383-385.
12. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
13. Song J.H., Tse M.C., Bellail A., et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 2007, 67:6946-6955.
14. Psahoulia F.H., Drosopoulos K.G., Doubravska L., et al. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 2007, 6:2591-2599.
15. Xu L., Qu X., Zhang Y., et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 2009, 583:943-948.
16. Merino D., Lalaoui N., Morizot A., et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 2006, 26:7046-7055.
17. Clancy L., Mruk K., Archer K., et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102:18099-18104.
18. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
19. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
20. Vitovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 2007, 282:31601-31609.
21. Labrinidis A., Liapis V., Thai le M., et al. Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood 2008, 111:5411-5412.
22. Zauli G., Secchiero P. Role of TRAIL in osteoclastogenesis. Blood 2008, 111:5413.
23. Sedger L.M., Glaccum M.B., Schuh J.C., et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 2002, 32:2246-2254.
24. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
25. Austin C.D., Lawrence D.A., Peden A.A., et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl. Acad. Sci. USA 2006, 103:10283-10288.
26. Wajant H. TRAIL and NFkappaB signaling - a complex relationship. Vitam. Horm. 2004, 67:101-132.
27. Varfolomeev E., Maecker H., Sharp D., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 2005, 280:40599-40608.
28. Baader E., Toloczko A., Fuchs U., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 2005, 65:7888-7895.
29. Ishimura N., Isomoto H., Bronk S.F., Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G129-G136.
30. Kavurma M.M., Schoppet M., Bobryshev Y.V., et al. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J. Biol. Chem. 2008, 283:7754-7762.
31. Chen X., Kandasamy K., Srivastava R.K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 2003, 63:1059-1066.
32. Bhoj V.G., Chen Z.J. Ubiquitylation in innate and adaptive immunity. Nature 2009, 458:430-437.
33. Jin Z., Li Y., Pitti R., et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
34. Cretney E., Shanker A., Yagita H., et al. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 2006, 84:87-98.
35. Falschlehner C., Schaefer U., Walczak H. Following TRAIL's path in the immune system. Immunology 2009, 127:145-154.
36. Finnberg N., Klein-Szanto A.J., El-Deiry W.S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 2008, 118:111-123.
37. Yue H.H., Diehl G.E., Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 2005, 12:94-97.
38. Cretney E., Takeda K., Yagita H., et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 2002, 168:1356-1361.
39. Takeda K., Smyth M.J., Cretney E., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 2001, 214:194-200.
40. Seki N., Hayakawa Y., Brooks A.D., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63:207-213.
41. Smyth M.J., Cretney E., Takeda K., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 2001, 193:661-670.
42. Grosse-Wilde A., Voloshanenko O., Bailey S.L., et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 2008, 118:100-110.
43. Wolf S., Mertens D., Pscherer A., et al. head and neck squamous cell carcinoma and bladder cancer. Int. J. Cancer 2006, 118:1831-1835.
44. Lee S.H., Shin M.S., Kim H.S., et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001, 20:399-403.
45. Fisher M.J., Virmani A.K., Wu L., et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 2001, 7:1688-1697.
46. Shin M.S., Kim H.S., Lee S.H., et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001, 61:4942-4946.
47. Wandinger K.P., Lunemann J.D., Wengert O., et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003, 361:2036-2043.
48. Rus V., Nguyen V., Puliaev R., et al. T cell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity. J. Immunol. 2007, 178:3962-3972.
49. Lub-de Hooge M.N., de Vries E.G., de Jong S., Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:854-858.
50. Rus V., Zernetkina V., Puliaev R., et al. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin. Immunol. 2005, 117:48-56.
51. Naka T., Sugamura K., Hylander B.L., et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002, 62:5800-5806.
52. Hylander B.L., Pitoniak R., Penetrante R.B., et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med. 2005, 3:22.
53. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
54. Ricci M.S., Kim S.H., Ogi K., et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12:66-80.
55. Rosato R.R., Almenara J.A., Coe S., Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007, 67:9490-9500.
56. Daniel D., Yang B., Lawrence D.A., et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007, 110:4037-4046.
57. Holland P.M., Miller R., Jones J., et al. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol. Ther. 2010, 9:539-550.
58. Herbst R.S., Mendelson D., Ebbinghaus S., et al. A Phase 1 safety and pharmacokinetic study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. 2006, 24. (Abstract 3013).
59. Yee L., Fanale M., Dimick K., et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J. Clin. Oncol. 2007, 25. (Abstract 8078).
60. Yee L., Burris H.A., Kozloff M., et al. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. J. Clin. Oncol. 2009, 27. (Abstract 4129).
61. Wiezorek J., Holland P., Graves J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res. 2010, 16:1701-1708.
62. Soria J.C., Smit E., Khayat D., et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1527-1533.
63. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl. J. Med. 2006, 355:2542-2550.
64. Kelley S.K., Harris L.A., Xie D., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 2001, 299:31-38.
65. Xin Y., Tohnya T.M., Herbst R.S., et al. Population pharmacokinetic analysis of ercombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a phase 1a study in advanced cancer and lymphoma. J. Clin. Oncol. 2008, 26. (Abstract 2525).
66. Ward T.H., Cummings J., Dean E., et al. Biomarkers of apoptosis. Br. J. Cancer 2008.
67. Pan Y., Xu R., Peach M., et al. Application of pharmacodynamic assays in a phase 1a trial of Apo2L/TRAIL in patients with advanced tumors. J. Clin. Oncol. 2007, 25. (Abstract 3535).
68. Wagner K.W., Punnoose E.A., Januario T., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
69. Stern H.M., Padilla M., Wagner K., et al. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin. Cancer Res. 2010, 16:1587-1596.
70. Rahman M., Davis S.R., Pumphrey J.G., et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat. 2008, 113:217-230.